Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile

Author(s)

Morau, Mariana Vieira ; Seguin, Cecilia Souto ; Perroud Junior, Mauricio Wesley ; Dagli-Hernandez, Carolina ; Pincinato, Eder de Carvalho ; Moriel, Patricia

• Document type: Journal article
• Source: PHARMACEUTICALS; v. 17, n. 8, p. 8-pg., 2024-08-01.

Abstract

Gefitinib is a selective inhibitor of the epidermal growth factor receptor that is used to treat advanced and metastatic non-small cell lung cancer (NSCLC). Dermatological adverse reactions are most commonly associated with gefitinib treatment. The cause of adverse reactions in individuals is multifactorial. Pharmacogenetics is an effective tool to detect such adverse reactions. This case report describes a female patient with NSCLC who was administered gefitinib at a dose of 250 mg/day. However, due to severe adverse dermatological reactions, the treatment was interrupted for 15 d and antibiotic therapy was administered to manage the skin rashes, maculopapular rashes, and hyperpigmentation. Treatment adherence was adequate, and no drug interactions were detected. A pharmacogenetic analysis revealed homozygosity in the ATP-binding cassette (ABC)-B1 rs1128503 (c.1236A>G), heterozygosity in ABCG2 rs2231142 (c.421G>T) and rs2622604 (c.-20+614T>C), and a non-functional variant of the cytochrome P450 family 3, subfamily A, member 5 (CYP3A5). The relationship between altered genetic variants and the presence of adverse reactions induced by gefitinib is still controversial. Overall, this case report highlights the importance of continuing to study pharmacogenetics as predictors of adverse drug reactions. (AU)

• FAPESP's process: 23/06280-7 - ADVERSE EVENTS OF TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER: CONTRIBUTION OF CLINICAL, GENETIC AND EPIGENETIC FACTORS
• Grantee: Patricia Moriel
• Support Opportunities: Regular Research Grants